Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Jul 04,2022
Medicilon and Xiling Lab formed a strategic partnership
On June 17, 2022, Shanghai Medicilon Inc. and Xiling Lab signed a strategic collaboration agreement on innovative drug research and development services in Tianfu Life Science Park.
More
Medicilon and Xiling Lab formed a strategic partnership
Jul 01,2022
Medicilon and BravoBio held an online ceremony for signing the Strategic Cooperation Agreement
On June 28, 2022, Shanghai Medicilon Inc. ("Medicilon”) and Shanghai BravoBio Co., Ltd ("BravoBio”) held an online ceremony for signing the Strategic Cooperation Agreement, which marks the two companies have officially become cooperative partners.
More
Medicilon and BravoBio held an online ceremony for signing the Strategic Cooperation Agreement
Jun 17,2022
Medicilon Appoints Dr. Jingxuan Zhang as Vice President of Preclinical Toxicology Research
​Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Jingxuan Zhang as the Vice President of the Preclinical Toxicology Research.
More
Medicilon Appoints Dr. Jingxuan Zhang as Vice President of Preclinical Toxicology Research
Jun 10,2022
Medicilon Assists | China's First CD19×CD3×CD28 Trispecific Antibody Obtained FDA Implicit Approval
Shanghai Medicilon Inc. (Medicilon) provided CC312 with a comprehensive preclinical study (including pharmacokinetics and safety evaluation) that complied with GLP specifications with compliant, efficient and high-quality services.
More
Medicilon Assists | China's First CD19×CD3×CD28 Trispecific Antibody Obtained FDA Implicit Approval
May 18,2022
Medicilon Appoints Dr. Jing Deng as Vice President of Pharmacology, Pharmacodynamics and Biology Department
Recently, Shanghai Medicilon Inc. (Medicilon, stock code: 688202.SH) announced the appointment of Dr. Jing Deng as the Vice President of the Pharmacology and Biology Department.
More
Medicilon Appoints Dr. Jing Deng as Vice President of Pharmacology, Pharmacodynamics and Biology Department
May 06,2022
Medicilon Assist| Sinovent's New Class 1 Anti-tumor Drug XNW14010 has been Approved for Clinical Trials
​Recently, the State Drug Administration approved the clinical application of XNW14010, a new class 1 anti-tumor drug from Evopoint Biosciences Co., Ltd. (hereinafter referred to as "Sinovent"), which is intended for the treatment of patients with Advanced solid tumors with KRAS G12C mutation.
More
Medicilon Assist| Sinovent's New Class 1 Anti-tumor Drug XNW14010 has been Approved for Clinical Trials
May 06,2022
Medicilon Assistant| Jimincare's lgE Antibody Drug JYB1904 has been Approved for Clinical Trials
JYB1904 is a new anti-IgE recombinant humanized monoclonal antibody targeted therapy drug. IgE is the main immunoglobulin that mediates type I hypersensitivity diseases.
More
Medicilon Assistant| Jimincare's lgE Antibody Drug JYB1904 has been Approved for Clinical Trials
May 05,2022
Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use
Recently, Bio-Thera Solutions, Ltd. (Bio-Thera) has been approved for clinical application of BAT8006 for injection.
More
Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use
May 05,2022
Lockdown Never Stopped; Resumption of Work Increases Efficiency
On the evening of March 27, right before the lockdown, Medicilon immediately launched the emergency plan in order to maintain the regular R&D work.
More
Lockdown Never Stopped; Resumption of Work Increases Efficiency
Apr 27,2022
Medicilon was selected into the Biomedicine Index
Shanghai Medicilon Inc. (Medicilon) was selected as a sample of the Biomedicine Index and became one of the top 5 heavyweight stocks.
More
Medicilon was selected into the Biomedicine Index
Apr 27,2022
Medicilon was awarded the Top Ten Drug Innovation Service Organizations of the Year in the 2021 Drug Innovation Award
On April 20th, the 2021 Drug Innovation Award sponsored by Securities Times, Medicilon was awarded the "Top Ten Drug Innovation Service Organizations of the Year" in the 2021 Drug Innovation Award.
More
Medicilon was awarded the Top Ten Drug Innovation Service Organizations of the Year in the 2021 Drug Innovation Award
Apr 27,2022
Medicilon won the "Top 50 China Best Employer Award 2021" on March 9
On March 9, the "Hi Liquid Workplace" 2021 China Annual Best Employer Awards Ceremony of the Yangtze River Delta region ended successfully online. Shanghai Medicilon Inc. (Medicilon) won the "Top 50 China Best Employer Award 2021."
More
Medicilon won the "Top 50 China Best Employer Award 2021" on March 9